Dr. Kamala K. Vasu

Total Experience 28 years

Educational Qualification : M.Sc., Ph.D

Research Area

Basic Research: Design and synthesis of New Chemical Entities [NCEs] for specific therapeutic areas like Inflammation, Cancer and Adenosine receptor ligands [Asthma], Alzheimer’s disease and Tuberculosis. More than 2000 NCEs have been synthesized.


General information
Designation: Assistant Director
Dean of Students’ Affairs & Head,
Office Phone 07927439375
Email kamalav@perdcentre.com

Brief about you

Dr. Kamala K. Vasu is Assistant Director, Dean of Student's Affairs and Head Department of Medicinal Chemistry. She has more than 28 years of research experience. She did her master’s and doctorate in Organic Chemistry from Osmania University, Hyderabad. Later she had been to Academia Sinica, Taipei, Taiwan for her Post Doctoral research work.

Her research interests are in the design and synthesis of NCEs for specific therapeutic areas like, for cancer, diabetes, Alzheimer's Disease , adenosine receptors and inflammation.

Her group has synthesized many novel thiazoles, thiophenes, imidzoles, quinazoline derivatives and screened for their activity. Many of the molecules were as potential NF-kB and AP-1 transcriptional expression inhibitors implicated in autoimmune diseases and cancer and also as adenosine receptor antagonists. She is also working in impurity profiling and synthesis of the impurities and in CADD and established the same in the institute

Outcome of her research has resulted in US and European patents and many international publications in peer review journals. In addition she has also filed for five Indian Patents and more than 55 more publications in peer reviewed journals.

She has collaborations with Lousiana State University, USA, Wurzberg University , Germany.

She has been teaching both undergraduates and the post graduate students. She has guided sixteen students for their Ph. D thesis and four are presently working. She has guided more than 30 M. Pharm. students for their project work. She has also given summer training to a number students from Gujarat and other states.

She has given a number invited lectures both in Gujarat and in other states. She has received many grants from Government and from Industries.

Basic Research

  • Cancer: More than 600 NCEs screened for their anticancer activity as inhibitors of NF- kB and AP-1 transcription factors. PMCR 242, a potential lead against prostate cancer is undergoing preclinical trials at LSU, USA. A collaborative project with Louisiana State University, USA.
  • Identification of novel ligands for Adenosine Receptors with selectivity for A1, A2A and A3 receptors- A collaborative work with Prof. Karl-Norbert Klotz, Germany. The above work has lead discovery of potent active and lead molecules like PMCDP-T2B7, PMCDP-T2B16, PMCDP-T2B21 and PMCDP-T2B22 against Parkinson’s diseases, Asthma, Alzheimer’s Disease, Inflammation and further development is in process.
  • Further more than 10 molecules with very good anti-cancer activity especially active against chemo sensitizing and chemo resistant strains. Developed in the institute.
  • Radioprotective agent: Developed a novel lead molecule as the radio protecting active molecule. There is only one drug Amifostene used for patients undergoing radiation therapy. Developed within the institute.

Applied Research

  • Impurity profiling and Stress degradation studies of Active Pharmaceutical Ingredients and their Formulations [Doxofylline, Trandrolapril, Irbesartan and PMCR-242 (in house product), Actarit, Bambuterol, Imidapril were carried out as per standard ICH guidelines].
  • Separation, identification and characterization of impurities.
  • Pharmacokinetic studies of bulk drug and in house lead molecules.
  • Bio analytical method development and validation of combination of drugs.
  • Stress degradation studies of herbal drugs and their formulations.

Current Activities

  • Dr. Kamala K. Vasu is Assistant Director, Dean of Student's Affairs and Head Department of Medicinal Chemistry. She has more than 28 years of research experience. She did her master’s and doctorate in Organic Chemistry from Osmania University, Hyderabad. Later she had been to Academia Sinica, Taipei, Taiwan for her Post Doctoral research work.
  • Her research interests are in the design and synthesis of NCEs for specific therapeutic areas like, for cancer, diabetes, Alzheimer's Disease , adenosine receptors and inflammation.
  • Her group has synthesized many novel thiazoles, thiophenes, imidzoles, quinazoline derivatives and screened for their activity. Many of the molecules were as potential NF-kB and AP-1 transcriptional expression inhibitors implicated in autoimmune diseases and cancer and also as adenosine receptor antagonists.
  • She is also working in impurity profiling and synthesis of the impurities and in CADD and established the same in the institute
  • As Dean of Student's Affairs, taking care of all the aspects right from admission of students for their Ph.D till their thesis submission. Catering to the need of the students from other Universities for their dissertation work and summer training programs.
  • As Purchase In charge looking into the smooth functioning of the system.
  • Safety and disaster management in charge. In charge of women safety cell.
Experience
Research 28 years
Teaching 10 years
Industry 1 year
Contact
Website www.perdcentre.com
Membership American Chemical Society, Indian Pharmaceutical Association
Specialization
Specialization Areas: Organic Chemistry / Medicinal Chemistry and Analytical Chemistry
Subject Taught UG: Organic reaction mechanisms, spectroscopy, topics in Physical chemistry like chemical kinetics, chemical equilibrium
Subject Taught PG: Basis of drug action, spectroscopy, stereochemistry, logic in organic synthesis, separation techniques, chiral separation, molecular docking and QSAR, chemistry of biomolecules, peptidomimetics.
Institute / Organization Designation Duration
B.V. Patel PERD Centre Assistant Director, Dean of Students Affairs & Head Department of Medicinal Chemistry 2006-Present
B.V. Patel PERD Centre Head, department of Medicinal Chemistry 1996 -Present
NIPER- Ahmedabad Faculty & Coordinator [Medicinal chemistry] 2010 -2014
NIPER- Ahmedabad Faculty & Coordinator [Common courses] 2007-2014
B.V. Patel PERD Centre In charge Head, Analytical Chemistry 2011-2013
Dishman Pharmaceuticals & Chemicals Ltd., Ahmedabad, Manager-Scientific 1995 -1996

A. International Journal :

Sr. No. Title ISSN / ISBN No Journal / Publisher Volume Year
Design, synthesis and biological evaluation of novel pyrazolo-pyrimidinones as DPP-IV inhibitors in diabetes Design, synthesis and biological evaluation of novel pyrazolo-pyrimidinones as DPP-IV inhibitors in diabetes 0960-894X Bioorganic & Medicinal Chemistry Letters   2015
Characterization of the degradation products of bambuterol using LCMS- QTOF and NMR 0003-2654 Analytical Methods   2015
Development and validation of stability-indicating HPLC method for imidapril and its degradation products using Design of Experiments (DoE) approach 1615-9314 Journal of Separation Science   2015
Novel thiazole–thiophene conjugates as adenosine receptor antagonists: Synthesis, biological evaluation and docking studies 0960-894X Bioorganic & Medicinal Chemistry Letters   2015
Stability-indicating assay method for determination of actarit, process related impurities and degradation products: Insight to intostability profile and degradation pathways 2097-1779 Journal of Pharmaceutical Analysis   2014
Implication of novel bis-imidazopyridines for management of Alzheimer’s disease and establishment of its role on protein phosphatase 2A activity in brain 2042-7158 Journal of Pharmacy and Pharmacology   2013
An efficient one pot synthesis of functionally diverse 2-aminothiazoles from isothiocyanates, amidines/guanidines and halomethylenes 0040-4039 Tetrahedron Letters 54 2013
CoMFA and CoMSIA 3D QSAR Models for a Series of Some Condensed Thieno[2,3-d]pyrimidin-4(3H)-ones with Antihistaminic (H1) Activity 1875-6638 Medicinal Chemistry 9 2013
New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides 0223-5234 European Journal of Medicinal Chemistry 63 2013
A concise, greener, solvent-free novel one-pot synthesis of trisubstituted thiophenes 0040-4039 Tetrahedron Letters 53 2012
A Diversified Assembly of 1,2,4 Oxadiazol-3-amines: Metallic Thiophile Catalyzed Chemoselective One-Pot Reaction of Aryl Isothiocyanates, Amidines/Guanidines, and Hydroxylamine 0039-7881 Synthesis 44 2012
An efficient, greener and solvent free one-pot synthesis of 3-substituted quinazolinones an thienopyrimidinones 0040-4039 Tetrahedron Letters 53 2012
An efficient synthesis of 2-Aminopyrroles from enaminone-amidine adduct and phenacyl/benzyl/heteroalkyl-halides 0040-4039 Tetrahedron Letters 52 2011
Gastroretentive delivery of refampicin: in vitro mucoadhesion and in vivo gamma scintigraphy 0378-5173 International Journal of Pharmaceutics 411 2011
Push-Pull osmotic pump for zero order delivery of lithium carbonate: development and in vitro characterization 1083-7450 Pharmaceutical Development and Technology   2011
Exploring the potential of polacrilin potassium as a novel superdistintegrant in microcrystalline cellulose based pellets prepared by extrusion-spheronization 2394-2002 Chronicles of Young Scientists 2 2011
A novel lipid based oral drug delivery system of Nevirapine 0974-4304 International Journal of Pharmaceutical Technology and Research 3 2011
Investigation of microemulsion system for transdermal delivery of itraconazole 0976-2094 Journal of Advanced Pharmaceutical Technology and Research 2 2011
Multivariate optimization of formulation and process variables influencing physico-mechanical characteristics of site-specific release isoniazid pellets 0378-5173 International Journal of Pharmaceutics 388 2010
A versatile one pot multicomponent synthesis of novel quinazolinon-2-yl-tetrasubstituted thiophenes 0040-4039 Tetrahedron Letters 51 2010
Push-pull osmotic pump for zero order delivery of lithium carbonate: development and in vitro Characterization 1097-9867 Pharmaceutical Development Technology   2010
Synthesis and evaluation of quinazolinone derivatives as inhibitors of NF-?B, AP-1 mediated transcription and eIF-4E mediated translational activation: Inhibitors of multipathways involve in cancer 0223-5234 European Journal of Medicinal Chemistry 45 2010
A convenient one-pot synthesis of trisubstituted 1,3,5-triazines through intermediary amidinothioureas 0040-4039 Tetrahedron Letters 51 2010
2-Amino-5-benzoyl-4-phenylthiazoles: development of potent and selective adenosineA1 receptor antagonists 0968-0896 Bioorganic & Medicinal Chemistry 18 2010
Design, synthesis and evaluation of novel 2-thiophen-5-yl-3H-quinazolin-4-one analogues as inhibitors of transcription factors NF-?B and AP-1 mediated transcriptional activation: Their possible utilization as anti-inflammatory and anticancer agents 0968-0896 Bioorganic & Medicinal Chemistry 18 2010
Synthesis, anti-inflammatory and HIV-1 integrase inhibitory activities of 1,2- bis[5-thiazolyl]ethane-1,2-dione derivatives 1998-3743 Indian Journal of Pharmaceutical Sciences 71 2009
A convenient synthesis of di- and trisubstituted 2-aminoimidazoles from 1-amidino-3-trityl-thioureas 0040-4039 Tetrahedron Letters 50 2009
Design, synthesis and characterization of novel 2-(2,4-disubstituted-thiazole-5-yl)-3-aryl- 3H-quinazoline-4-one derivatives as inhibitors of NF-kB and AP-1 mediated transcription activation and as potential anti-inflammatory agents. 0223-5234 European Journal of Medicinal Chemistry 44 2009
Synthesis of 4-benzyl- 1,3-thiazole derivatives as potential anti-inflammatory agents: an analogue-based design approach 1475-6374 Journal of Enzyme Inhibition and Medicinal Chemistry 24 2009
Pair wise binding affinity: 3D QSAR studies on a set of triazolo [1, 5-a] quinoxalines as antagonists of AMPA and KA receptors 1475-6374 Journal of Enzyme Inhibition and Medicinal Chemistry 24 2009
A facile synthesis of structurally novel 1-aryl-2-arylamino-4-alkyl/phenyl- 5-aroyl-1H-imidazoles from amidinothioureas. 0040-4039 Tetrahedron Letters 49 2008
2-Amino-5-thiazolyl motif: A novel scaffold for designing anti-inflammatory agents of diverse structures 0223-5234 European Journal of Medicinal Chemistry 43 2008
3D-QSAR Studies for the Binding Affinity toward (R,S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor 1846-9558 Acta Pharmaceutica 58 2008
Dissolution test for site specific release isoniazid pellets in USP apparatus 3 (reciprocating cylinder):Optimization using response surface methodology 0939-6411 European Journal of pharmaceutics and Biopharmaceutics 69 2009
Syntheses of new tetrasubstitutedthiophenes as novel anti-inflammatory agents 0223-5234 European Journal of Medicinal Chemistry 42 2007
Tetra substituted thiophenes as anti-inflammatory agents: exploitation of analogue-based drug design 0968-0896 Bioorganic and Medicinal Chemistry 13 2005
QSAR studies on some thiophene analogs as anti-inflammatory agents: enhancement of activity by electronic parameters and its utilization for chemical lead optimization 0968-0896 Bioorganic and Medicinal Chemistry 13 2005
Design, synthesis, and pharmacological evaluation of some 2-[4-morpholino]-3-aryl-5-substituted thiophenes as novel anti-inflammatory agents: generation of a novel anti-inflammatory pharmacophore 0968-0896 Bioorganic and Medicinal Chemistry 12 2004
Design, synthesis and SAR studies of some 5-aliphatic oximino esters of thiophene as potential anti inflammatory leads: comparative biological activity profile of aliphatic oximesvs aromatic oximes 0006-291X Biochemical and Biophysical research 4 2004
Novel drug designing approach for dual inhibitors as anti-inflammatory agents: implication of pyridine template 0006-291X Biochemical and Biophysical research 1 2003
Altered Glucose Tolerence by a Guanidinethiourea compound in spragueDawley Rats: Possible Mechanism(s) for Hyperglycemia 0019-462X Indian Drugs 41 2004
Selective Tritylation of 5’-hydroxyl group in Nucleosides & Internal Acid catalysed N-Detritylation of nucleosides 0366-0370 Bulletin of the Institute of Chemistry, Academia Sinica 40 1993
Synthesis of 1-(5-Methylisoxazole-3-yl)- 5- aryl-tetrazoles and Its Pyrolysis 0975-0975 Indian Journal of Chemistry 29B 1990
Synthesis of 2-aroyliminobenzothiazolomido 3,2-1,2,4-thiadiazolines 0975-0975 Indian Journal of Chemistry 29B 1990
Synthesis of 2-aroyliminopyrimido (3,2-b),1,2,4- thiadiazolines 0039-7911 Synthetic Communications 19 1989
Synthesis of 2-aryl-s-triazolo (1, 5-a) pyirimidines 0009-2673 Bulletin of the Chemical Society of Japan 61 1988
Synthesis, photolysis & Pyrolysis of 1-(2-benzothiazolyl)-5-aryl tetrazole 0975-0975 Indian Journal of Chemistry 22B 1983

B. National Journal :

Sr. No. Title ISSN / ISBN No Publisher Volume Year
Altered Glucose Tolerence by a Guanidinethiourea compound in spragueDawley Rats: Possible Mechanism(s) for Hyperglycemia 0019-462X Indian Drugs 41 2004
Synthesis of 1-(5-Methylisoxazole-3-yl)- 5- aryl-tetrazoles and Its Pyrolysis 0975-0975 Indian Journal of Chemistry 29B 1990
Synthesis of 2-aroyliminobenzothiazolomido 3,2-1,2,4-thiadiazolines 0975-0975 Indian Journal of Chemistry 29B 1990
Synthesis, photolysis & Pyrolysis of 1-(2-benzothiazolyl)-5-aryl tetrazole 0975-0975 Indian Journal of Chemistry 22B 1983

C. Conference attended:

Sr. No. Title
Giri, R.S., Franklin, P.X., Pillai, A.D., Rathod, P.D., Vasu, K.K., and Sudarsanam, V. Discovery drug delivery system of Itraconazole at 6th International Symposium on Innovations in Pharmaceutical Sciences and Technology, Ahmedabad 26th to 28th November 2010
Pund S., Joshi A., Vasu K., Nivsarkar M., and Shishoo C. Gastroretentive delivery of rifampicin: in vitro mucoadhesion and in vivo gamma scintigraphy. 6th International Symposium of Innovations in Pharmaceutical Sciences and Technology, Ahmedabad, Nov. 2010.
Joshi, A., Pund, S., Nivsarkar, M., Vasu, K., Shishoo, C. Exploring the potential of polacrilin potassium as a superdisintegrant in mcc based pellets prepared by extrusionspheronization 6th International Symposium on Innovations in Pharmaceutical Sciences and Technology, Ahmedabad 26th to 28th November 2010
Pund S., Joshi A., Vasu K., Nivsarkar M., and Shishoo C. Oral delivery of anti-tubercular drugs- Improving rifampicin stability and bioavailability. FIP Pharmaceutical Sciences 2010 World Congress in association with the AAPS Annual Meeting and Exposition. New Orleans, Lousiana, USA. Nov. 2010.
R. P. Joshi , A. Abiramasundari, Kamala K of 5-thiazolyl ketoxime fragment as a pharmacophore for TNF-a release inhibition. Presentation at the 241th ACS National Meeting, Anaheim, California, USA, March, 2011 (Document ID: 16187).
Patel, V., Chudasama, A., Nivsarkar, M., Vasu, K., Shishoo, C. Development and in vitro characterization of push - pull osmotic pump for zero order delivery of lithium carbonate at 6th International Symposium on Innovations in Pharmaceutical Sciences and Technology, Ahmedabad , Nov. 2010.
Chudasama A., Patel V., Nivsarkar M., Shishoo, C., Vasu, K., Development and evaluation of self emulsifying Vasu, Investigation and Structural elucidation of hydrolytic degradation products of Doxofylline, 6th International Symposium, Nov. 26th -28th 2010, Ahmedabad.
Baraiya A. B., Kaila J. C., Pandya A. N., Jalani H.B, Srihasam L., Kamala K Vasu, Design and synthesis of novel 2-aminoimidazole-2-aminothiazole conjugates as inhibitors of NF-?B/AP-1 mediated transcriptional activation: IMPLICATION as potential anti-cancer agents, 6th International Symposium, Nov. 26th -28th 2010, Ahmedabad.
Amit N. Pandya, Jitendra C Kaila, Arshi B. Baraiya, Hitesh B. Jalani, Sonja Kachler, Karl Norbert Klotz, Kamala K. Vasu. 2-Aminoimidazole Motif: A novel scaffold for the design of selective human adenosine A3 receptor antagonist, 6th International Symposium, Nov. 26th -28th 2010, Ahmedabad.
Lakshmi S., Shah N., Khatri K., Singh R.,Kaila J., Vasu K. Evaluation of selectiveradioprotective effects of novel NF-kB activators. 6th International Symposium, Nov.26th -28th 2010, Ahmedabad
HemRaj., Baraiya A.B., VasuK.K., Lakshmi S. Chemosenstizing effect of novel NF-kB Inhibitor in various cancer cell lines. 6th International Symposium, Nov.26th -28th 2010, Ahmedabad
Carroll JL, Adams LK, Rogers DL, Galiano F J, Giri R.S, Williams J. et al. Novel 2- thiazol or 2-thiophen-substituted quinazolinone derivatives with significant anti-tumor effects, Drug discovery section, 100th AACR meeting, Denver, CO, 2009.
Chudasama A., Shishoo C., Vasu, K.,“Design and Characterization of Microemulsion based topical delivery of Itraconazole”at 61st Indian Pharmaceutical Congress, Ahmedabad, December 2009.
Pund, S., Joshi, A., Vasu, K.K., Nivsarkar, M. Gastroretentive delivery System of Rifampicin: In-vitro Mucoadhesion and in-vivo Gamma Scintigraphy. GUJCOST oral paper presentation competition, Gujarat, Jan.2009.
Chudasama A., Shishoo C., Vasu, K., Development and Evaluation of Self Emulsifying Drug Delivery System of Nevirapine” at 60th Indian Pharmaceutical Congress, New Delhi, December 2008.
Giri R.S., Williams J., Sudersanam V. Vasu K.K., “Discovery of PMCR-75 as an inhibitor of AP-1: A Potential anti-cancer agent” at the Gujarat Council of Science and technology, Gujarat, India, 2007.
Pund, S., Joshi, A., Vasu, K., Nivsarkar, M., Shishoo C. Study of solid-solid interaction of rifampicin and isoniazid by differential scanning calorimetry. 1st Indo-Japanese International Joint Symposium on overcoming intractable infectious diseases, Tokyo, Nov. 2007.
Joshi, A., Pund, S., Nivsarkar, M., Vasu, K., Shishoo, C. Functionality comparison of superdisintegrants in promoting dissolution of rifampicin pellets. 12th APTI Annual Convention, Chandigarh, Oct. 2007.
Pund, S., Joshi, A., Vasu, K., Nivsarkar, M., Shishoo C. An application of Plackett-Burman design to study factors influencing dissolution from isoniazid pellets in USP app 3. 12th APTI Annual Convention, Chandigarh, Oct. 2007.
Joshi, A., Pund, S., Nivsarkar, M., Vasu, K., Shishoo, C. Design and development of a novel site-specific delivery system of rifampicin and isoniazid for improved stability and bioavailability. 1st Indo-Japanese International Joint Symposium on overcoming intractable infectious diseases, Tokyo, Nov. 2007.
Siddharth M. Parekh, Prof. R. N. Shukla, Dr. Kamala Vasu, Nitration of Aromatic Compounds without Using Sulphuric Acid, The 2007 Spring National Meeting Houston, TX (Poster 127a), April 22- 26, 2007, USA
Giri R.S, Yerande S.G, Inamdar G.S, Thakar H.M, Franklin P.X, Vasu K.K, Sudarsanam V. Synthesis and pharmacological evaluation of SYPERD-17, a selective A2A antagonist, as antiparkinsonian agent, 9th Annual meeting of International Society for Chemists & Biologists , Lucknow, India, 2006.
Pund, S., Joshi, A., Vasu, K., Nivsarkar, M., Shishoo C. MUPS of Rifampicin- A Novel Formulation Approach. 58th Indian Pharmaceutical Congress, Mumbai, Dec. 2006.
Pund S., Joshi A., Vasu K., Shishoo C. Design and evaluation of Oro-dispersible meloxicam tablets with improved taste and dissolution characteristics. 11th APTI Annual Convention, Bangalore, Sept. 2006.
Giri R.S, Franklin P.X, Yerande SG, Inamdar G.S, Thakar H.M, Vasu K.K, Sudarsanam V.
Template based approach for the designing of the novel anti-inflammatory agents, 1st Indo-Japanese International conference on Advances in Pharmaceutical research and Technology, Mumbai, India, 2005.
Inamdar G.S, Yerande S.G, Thakar H.M, Giri R.S, Sudarsanam V, Vasu K.K, 2-[4- morpholino-3-aryl-5-substituted]thiophene as novel adenosine A3 antagonist, 1st Indo- Japanese International conference on Advances in Pharmaceutical research and Technology, Mumbai, India, 2005.
Yerande S.G, Vasu K.K, Franklin P.X, Thakar H.M, Inamdar G.S, Giri R.S, Sudarsanam V. 1,2-Bis[2-amino-5-thiazolyl]ethane-1,2-dione derivatives as HIV-Integrase inhibitors, 1st Indo-Japanese International conference on Advances in Pharmaceutical research and Technology, Mumbai, India, 2005.
Giri R.S, Thakar HM, Vasu K.K, Sudarsanam V, CoMFA Study of tetra substituted imidazoles: Inhibitors of p38 MAP Kinase, 57th Indian Pharmaceutical Congress, Hyderabad, India, 2005.
Carroll JL, Adams LK, Rogers DL, Galiano F J, Giri R.S, Williams J. et al. Novel 2- thiazol or 2-thiophen-substituted quinazolinone derivatives with significant anti-tumor effects, Drug discovery section, 100th AACR meeting, Denver, CO, 2009.
Chudasama A., Shishoo C., Vasu, K.,“Design and Characterization of Microemulsion based topical delivery of Itraconazole”at 61st Indian Pharmaceutical Congress, Ahmedabad, December 2009.
Pund, S., Joshi, A., Vasu, K.K., Nivsarkar, M. Gastroretentive delivery System of Rifampicin: In-vitro Mucoadhesion and in-vivo Gamma Scintigraphy. GUJCOST oral paper presentation competition, Gujarat, Jan.2009.
Chudasama A., Shishoo C., Vasu, K., Development and Evaluation of Self Emulsifying Drug Delivery System of Nevirapine” at 60th Indian Pharmaceutical Congress, New Delhi, December 2008.
Giri R.S., Williams J., Sudersanam V. Vasu K.K., “Discovery of PMCR-75 as an inhibitor of AP-1: A Potential anti-cancer agent” at the Gujarat Council of Science and technology, Gujarat, India, 2007.
Giri R.S, Thakar HM, Vasu K.K, Sudarsanam V, CoMFA Study of tetra substituted imidazoles: Inhibitors of p38 MAP Kinase, 57th Indian Pharmaceutical Congress, Hyderabad, India, 2005.
TAB 4 Pund, S., Joshi, A., Vasu, K., Nivsarkar, M., Shishoo C. Study of solid-solid interaction of rifampicin and isoniazid by differential scanning calorimetry. 1st Indo-Japanese International Joint Symposium on overcoming intractable infectious diseases, Tokyo, Nov. 2007.
Joshi, A., Pund, S., Nivsarkar, M., Vasu, K., Shishoo, C. Functionality comparison of superdisintegrants in promoting dissolution of rifampicin pellets. 12th APTI Annual Convention, Chandigarh, Oct. 2007.
Pund, S., Joshi, A., Vasu, K., Nivsarkar, M., Shishoo C. An application of Plackett-Burman design to study factors influencing dissolution from isoniazid pellets in USP app 3. 12th APTI Annual Convention, Chandigarh, Oct. 2007.
Joshi, A., Pund, S., Nivsarkar, M., Vasu, K., Shishoo, C. Design and development of a novel site-specific delivery system of rifampicin and isoniazid for improved stability and bioavailability. 1st Indo-Japanese International Joint Symposium on overcoming intractable infectious diseases, Tokyo, Nov. 2007.
Siddharth M. Parekh, Prof. R. N. Shukla, Dr. Kamala Vasu, Nitration of Aromatic Compounds without Using Sulphuric Acid, The 2007 Spring National Meeting Houston, TX (Poster 127a), April 22- 26, 2007, USA
Giri R.S, Yerande S.G, Inamdar G.S, Thakar H.M, Franklin P.X, Vasu K.K, Sudarsanam V. Synthesis and pharmacological evaluation of SYPERD-17, a selective A2A antagonist, as antiparkinsonian agent, 9th Annual meeting of International Society for Chemists & Biologists , Lucknow, India, 2006.
Pund, S., Joshi, A., Vasu, K., Nivsarkar, M., Shishoo C. MUPS of Rifampicin- A Novel Formulation Approach.
Pund S., Joshi A., Vasu K., Shishoo C. Design and evaluation of Oro-dispersible meloxicam tablets with improved taste and dissolution characteristics. 11th APTI Annual Convention, Bangalore, Sept. 2006. 58th Indian Pharmaceutical Congress, Mumbai, Dec. 2006.
Giri R.S, Franklin P.X, Yerande SG, Inamdar G.S, Thakar H.M, Vasu K.K, Sudarsanam V.
Template based approach for the designing of the novel anti-inflammatory agents, 1st Indo-Japanese International conference on Advances in Pharmaceutical research and Technology, Mumbai, India, 2005.
Inamdar G.S, Yerande S.G, Thakar H.M, Giri R.S, Sudarsanam V, Vasu K.K, 2-[4- morpholino-3-aryl-5-substituted]thiophene as novel adenosine A3 antagonist, 1st Indo- Japanese International conference on Advances in Pharmaceutical research and Technology, Mumbai, India, 2005.
Yerande S.G, Vasu K.K, Franklin P.X, Thakar H.M, Inamdar G.S, Giri R.S, Sudarsanam V. 1,2-Bis[2-amino-5-thiazolyl]ethane-1,2-dione derivatives as HIV-Integrase inhibitors, 1st Indo-Japanese International conference on Advances in Pharmaceutical research and Technology, Mumbai, India, 2005.

D. PATENTS

International
Thiazole and Thiophene Analogues and their use in treating autoimmune diseases and cancers” US patent publication no. US 8217037 B2
European patent publication no. EP 2007393 B1
Patents have been filed in Australia, Canada and India.
National
Oral gastro retentive fixed dose pharmaceutical compositions for the treatment of tuberculosis and process for preparation thereof’ Application No: 2829/MUM/2009
Novel pyrazoles and pyrazolopyrimidinones: Application no. 1918/MUM/2013
Novel imidazo 1,3,5-triazinyl thiazoles: Application no. 1919/MUM/2013
New use of 2-substituted amino-5-thiazolyl analogues against diabetes, obesity and autoimmune diseases Application no. 1920/MUM/2013
Novel 2-substituted thiazole compounds. Application no. 2294/MUM/2014.
(5-thiazolyl/thienyl)-2-thienyl methanones. Application no. 2295/MUM/2014.
Qualification Specialization University Passing Year
Post Doctoral Fellow Organic/Medicinal Chemistry Institute of Chemistry, Academia , Taipei, Taiwan 1991-1994
Post Doctoral Fellow Organic Chemistry [Synthetic] Department of Chemistry, Osmania University 1986 -1991
Ph.D. Organic Chemistry [Synthetic] Synthesis of novel heterocyclic From 2-aminobenzothiazoles, 2-aminopyrimidines and 3- aminoisoxazoles Osmania University, Hyderabad 1981 -1986
M.Sc Organic Chemistry [Synthetic] Osmania University, Hyderabad 1978-1980
B.Sc. Botany, Zoology & Chemistry SNVMV College, Osmania University 1975 -1978
Activity Type Activity Title Place Date Faculty Role
Administration In charge of IC projects B.V. PERD Centre Since , 2009 Implementation and execution of projects
As Dean of Students Affair's B.V. PERD Centre Since 2006 Getting recognition as research guides for the faculties from different universities in Gujarat
Streamlined the process for the admission of students for Ph. D, and for M.Pharm / M.Sc dissertation and summer training programs for students from other colleges/universities/Institutes from all over India.
Since 2004 Established Computer Aided Drug Design in PERD Centre for the benefit of PERD students and faculties.
Purchase In charge B.V. PERD Centre Since 2012
Safety and Disaster Management Incharge
Academic B.V. PERD Centre Since 1996 Key roles organization of workshops
Coordinator and as faculty lecturer
Invited as lecturer for refresher courses

A. Government Project

Sr. No. Fund Type Agency Start Date Duration Principal Investigator
External Funding DST -SERB 2015 3 Years Dr. Kamala K. Vasu
External Funding GSBTM 2013 2 years Dr. Kamala K. Vasu
Internal Funding PERD Centre 2009 4 Years Dr. Kamala K. Vasu
Internal Funding PERD Centre 2007 4 Years Dr. Kamala K. Vasu
External Funding DBT 2006 3 Years As Co-Investigator
External Funding DST -SERB 2010 2 Years Dr. Kamala K. Vasu
External Funding DBT 2009 3 Years As Co-Investigator
External Funding DST –PRDS scheme 2006 3 years Dr. Kamala K. Vasu
External Funding Industry Related 2003 Continuing Dr. Kamala K. Vasu
External Funding ICMR 2003 3 Years Dr. Kamala K. Vasu
External Funding GUJCOST 2000 2 Years Dr. Kamala K. Vasu
External Funding Industry 1999 1 Year Dr. Kamala K. Vasu
Internal Funding PERD Centre 1996 In process Dr. Kamala K. Vasu